+ Watch CBPO
on My Watchlist
A sound investment for the End of Times.
This is a tracking portfolio of all CAPS-ratable tickers in the Chinese RTO/SPAC space (i.e., companies that listed without filing an IPO).China Biologic Products, Inc. went public via a reverse merger in 2006. The company is based in China.
*China Biologic is the largest publically owned blood center in China. *The government is committed to pouring in $$ to increase health care by 15% per year for at least the next five years. CBPO will be one of the major beneficiaries. *They have a government-protected moat.*They have just opened up two new collection centers.*They have not even scratched the surface of international sales where their margins will be even larger.
looks undervalued, good time to buy.
I looked at the top bull pitch and thought, wow that is a better bear pitch except for appearing on the MFI list. This company seems to be one of the few undervalued companies on my list. The growth is pretty outstanding. I don't understand the comment that most of the long-term debt would be coming due in 2010. If that were so, it wouldn't be considered long-term debt, it would show up under short-term debt. Regardless of those assumptions, the P/E is high, but there is pretty good growth ahead, especially in the high-flying economy of China. They do not have the debt and tax problems the U.S. does, and they are going to let their currency rise in value. Why people think inflation and devaluation of currency is good is beyond me. Increased valuation means that the average worker can buy more for their wages. Inflation hurts average savers and only helps the wealthy who have their money in investments that increase greater than inflation. Wages are going up slower than inflation, but they always ignore food and oil in the 'core' inflation figure. To me the core inflation should be those very items and exclude everything else.In other words, China's economy will increase, while America's will decline or stagnate on real terms, and any growth will be through inflation, which only appears on paper.
I THINK WOULD THIS WOULD DEFINITELY OUT PERFORM THE OTHER BECAUSE IN ONE YEAR IT EARN MORE THAN 230% OF WHAT WAS STARTED WITH
Great new growth stock, single largest blood plasma collector - low P/E
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions